Inclusion Criteria:

1. The sex does not limit, age:18-70 years old ;

2. The patients have inoperable advanced hepatoma without serious disorder in liver and
renal, tumor occupation< 70 %;

3. The patients have failure in surgical intervention or resection operation recidivist;

4. Hepatic function Child-pugh A、B;

5. All the cases have the definite final diagnosis of imageology results such as MRI、CT
、B ultrasonic or cytology results ;

6. The patient's prediction of live time>6 months, who can tolerant of TACE and has
quality of life ECOG score<3;

7. The patients participate the clinical trial voluntarily and have already signed
informed consent.

Exclusion Criteria:

1. Main portal vein was obstructed completely;

2. The occupation of tumour are 70 % or more than 70 % in the whole liver;

3. The patient has recepted TACE or other antineoplaston;

4. After carcinosectomy the patient has the prophylactic;

5. The patient is with renal inadequacy: Cr≥133 umol/L

6. Severe cardiovascular disease;

7. The patient is with other diseases to influence the proposal;

8. All over the body generally have metabasis or be with other malignant neoplastic
disease;

9. In the process of participation of other medicinal trial;

10. Gravidity, lactation ,hypersensitiveness constitution or have already known adverse
reaction or taboo.